Download Files:
(S)-Ceralasertib
$350 – $2,650
Products Details
Product Description
– (S)-Ceralasertib ((S)-AZD6738) is extracted from patent WO2011154737A1, Compound II, exhibits an IC50 of 2.578 nM[1].
(S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical and pharmacokinetic (PK) characteristics.
(S)-Ceralasertib is developed improving aqueous solubility and eliminates CYP3A4 time-dependent inhibition[2].
Web ID
– HY-19323A
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C20H24N6O2S
References
– [1]By Foote, et al. Morpholinopyrimidines as ATR kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. PCT Int. Appl. (2011), WO 2011154737 A1 20111215.|[2]Foote KM, et al. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutatedand Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. J Med Chem. 2018 Nov 21;61(22):9889-9907.
CAS Number
– 1352226-87-9
Molecular Weight
– 412.51
Compound Purity
– 98.84
SMILES
– O=[S@](C1(CC1)C2=NC(C3=C4C(NC=C4)=NC=C3)=NC(N5CCOC[C@H]5C)=C2)(C)=N
Clinical Information
– Phase 3
Research Area
– Cancer
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– ATM/ATR
Pathway
– Cell Cycle/DNA Damage;PI3K/Akt/mTOR
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
